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Sarah Nasser, Katherine Wong, Paul Naylor, Murray Ehrinpreis and Milton Mutchnick.
Detroit Medical Center
• Identifying patients with cirrhosis is
complicated, but Ultrasound based Transient
Elastography (TE;FibroScan) for non-invasive
assessment of fibrosis may offer a more
accurate approach than serum-based cirrhosis
determination.
• The objective of our study was to use a
FibroScan database to identify patients with
cirrhosis in our primarily African American
(AA) Hepatitis C (HCV) patients.
• Cirrhotic patients were used to compare
FibroScan to serum assessments of fibrosis
and to track outcomes for HCV patients.
• Of 332 individuals with a FibroScan evaluation of
fibrosis between 2014 and 2016, 79 (24%) had a
score of >12.5 kPa (cirrhosis). Their electronic
medical records were reviewed, risk factor for
cirrhosis determined and outcomes evaluated.
• Data analysis was performed using the SAS-JMP
statistical software.
• Serum based fibrosis was calculated using the
AST to Platelet Ratio Index (APRI) and Fibrosis-
4 (FIB-4) within a year of the FibroScan. An
APRI score >0.7 and FIB-4 score >3.25 was used
for predicting advanced fibrosis/cirrhosis.
APRI= ((AST value /AST upper limit)/Platelet Count) x 100
FIB-4= (Age(years) x AST)/(Platelet Count x Sqrt(ALT))
Figure 1:  APRI and FIB-4 Scores as compared to FibroScan scores for the patients with cirrhosis (kPa >12.5). 
The green line represents the literature cut-off typically used to identify patients with significant 
fibrosis/cirrhosis by the serum-based assays.  The primary advantage of FibroScan is in identifying 
patients with early cirrhosis where the serum assessment has the lowest sensitivity and specificity. 
Figure 2:  Change in FibroScan values as a function of treatment.  The upper graph plots the initial and 
subsequent FibroScan result for patients who were not treated or who were treated and achieved viral 
clearance (Sustained Viral Response (SVR)).  The lower graph  is a plot of the improvement in FibroScan 
value. Using pair wise analysis, the patients who achieved an SVR has a significant improvement (p<0.005) 
while those who were not treated did not.






In patients who had FibroScan-defined cirrhosis, neither their APRI nor FIB-
4 scores were as reliable as FibroScan for identifying patients with cirrhosis 
(Figure 1). The data in Figure 1 plots the FibroScan score vs the two serum 
assessment values as continuous variables. The primary failure to identify 
cirrhosis was due to low serum-based scores in patients who had early 
cirrhosis as defined by FibroScan. 
• Patients with a subsequent FibroScan after HCV eradication, had a 
statistically significant improvement in fibrosis if they achieved 
SVR as compared to the non-treated patients (p<0.005) (Figure 2). 
• Only 1 patient developed decompensation in the SVR group (1/40= 
3%) as compared to non responders or not treated patients (3/5= 
60%; p<0.0001)
• FibroScan is better than serum-based assays for 
identifying early cirrhosis in HCV patients.
• Identifying regression of cirrhosis scores after HCV 
eradication is also a potential utility for the methodology. 
• Regression of cirrhosis may predict decreased risk for 
decompensation, hepatocellular carcinoma and 
esophageal varices. 
• Further studies evaluating the relationship between 
improvement in Fibrosis by FibroScan and the 
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Change in Repeat FibroScan Value by Treatment (SVR) vs No Treatment 
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Decrease (Improvement)  in FibroScan Value as a Function of Treatment
Patient Population
Cirrhotic HCV patients were 92% AA and  52% male. FibroScan 
values ranged from 12.5 to 75 with a mean of 25.5 kPa for AA and 
28.0 kPa for Non-AA. Most HCV patients (82%) were treated after 







Outcomes for patients with HCV were tracked using two criteria:
a) improvement in FibroScan scores, and 
b) development of decompensated cirrhosis.  
